|
|
Office Locations:
|
1 Embarcadero Center, 12th Floor
San Francisco, CA 94111
Phone: 650-447-4266
| | |
|
|
|
|
Life Sciences & Healthcare
Medical Device
|
|
|
Nexus NeuroTech Ventures is a venture capital firm based in San Francisco committed to advancing breakthrough technologies for brain disorders. The firm makes seed and series A-C investments, and have the unique capacity to support earlier-stage programs not yet ready for formal venture capital investment through its Nexus NeuroTech Incubator Program. Founded in 2023 by Jordi Parramon, PhD and William Marks, MD the firm brings a deep commitment to helping those with neurological and psychiatric disorders, such as Parkinson's disease, bipolar disorder, and autism. Adjacent to these sentinel disorders are many other brain disorders that are also within scope for Nexus NeuroTech Ventures.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
